|Mr. Robert Forrester LL.B.||Chief Exec. Officer, Pres and Director||858.69k||N/A||53|
|Mr. Daniel W. Paterson||Chief Operating Officer||541.29k||N/A||56|
|Dr. Gregory I. Berk M.D.||Sr. Advisor and Member of Clinical & Scientific Advisory Board||565.33k||N/A||59|
|Mr. Richard H. Aldrich Mba||Founder and Consultant||N/A||N/A||63|
|Dr. Robert A. Weinberg Ph.D.||Co-Founder and Chair of Scientific Advisory Board||N/A||N/A||N/A|
Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The companys defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. The companys duvelisib is in Phase 3 randomized and two-arm trial for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with refractory indolent non-Hodgkin lymphoma. The company has license agreement with Infinity Pharmaceuticals, Inc.; The Scripps Research Institute; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts.
Verastem, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 9. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 9.